Compare FMY & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMY | NEPH |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 60.0M |
| IPO Year | N/A | 2004 |
| Metric | FMY | NEPH |
|---|---|---|
| Price | $11.87 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 10.1K | ★ 74.6K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $17,930,000.00 |
| Revenue This Year | N/A | $33.32 |
| Revenue Next Year | N/A | $12.27 |
| P/E Ratio | ★ N/A | $36.15 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $10.71 | $1.39 |
| 52 Week High | $12.17 | $6.42 |
| Indicator | FMY | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 48.33 |
| Support Level | $11.87 | $4.83 |
| Resistance Level | $11.93 | $5.97 |
| Average True Range (ATR) | 0.07 | 0.63 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 13.99 | 28.93 |
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.